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Elimination of quiescent/slow-proliferating cancer
stem cells by Bcl-XL inhibition in non-small cell lung
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M Todaro2, G Stassi2 and R De Maria3
Lung cancer is the most common cause of cancer-related mortality worldwide, urging the discovery of novel molecular targets
and therapeutic strategies. Stem cells have been recently isolated from non-small cell lung cancer (NSCLC), thus allowing the
investigation of molecular pathways specifically active in the tumorigenic population. We have found that Bcl-XL is constantly
expressed by lung cancer stem cells (LCSCs) and has a prominent role in regulating LCSC survival. Whereas chemotherapeutic
agents were scarcely effective against LCSC, the small molecule Bcl-2/Bcl-XL inhibitor ABT-737, but not the selective Bcl-2
inhibitor ABT-199, induced LCSC death at nanomolar concentrations. Differently from gemcitabine, which preferentially
eliminated proliferating LCSC, ABT-737 had an increased cytotoxic activity in vitro towards quiescent/slow-proliferating LCSC,
which expressed high levels of Bcl-XL. In vivo, ABT-737 as a single agent was able to inhibit the growth of LCSC-derived
xenografts and to reduce cancer stem cell content in treated tumors. Altogether, these results indicate that quiescent/
slow-proliferating LCSC strongly depend on Bcl-XL for their survival and indicate Bcl-XL inhibition as a potential therapeutic
avenue in NSCLC.
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Lung cancer is the leading cause of cancer-related death in
men and is expected to become the main cause of cancer
death for women in the near future.1,2 There is increasing
evidence that cancer stem cells (CSCs) have a key role in
drug resistance, tumor progression and metastasis in multiple
tumor types, including lung cancer.3 Lung cancer stem cells
(LCSCs) have been previously identified through different
criteria including surface expression of CD133, c-kit or
through functional properties such as selective drug survival,
elevated aldehyde dehydrogenase (ALDH) activity, increased
glycolysis and glycine/serine metabolism or low concentra-
tions of reactive oxygen species and ATP.4–9 Importantly,
when inoculated into immunocompromised mice, LCSCs give
rise to xenografts that histologically reproduce the tumor of
origin, thus representing an improved model for in vivo testing
of new targeted therapies.10 Several tumors express elevated
levels of anti-apoptotic Bcl-2 family proteins such as Bcl-2,
Bcl-XL and Mcl-1, which affect the apoptotic threshold of
neoplastic cells contributing to chemotherapy resistance.11
Inhibition of anti-apoptotic Bcl-2 family members has been for
long time regarded as a promising strategy to induce cancer
cell death through approaches of increasing specificity. BH3
mimetics such as ABT-737, the related orally available ABT-
263 (navitoclax) and the recently developed Bcl-2-selective
inhibitor ABT-199 have been shown to exert an antitumor
effect in preclinical and clinical settings either as single agents
or in combination with conventional or targeted drugs.12
Recently, a new role for Bcl-2 has emerged in acute myeloid
leukemia (AML), where quiescent stem cells characterized by
low levels of reactive oxygen species were found to over-
express Bcl-2 and rely on this factor for survival.13 Similarly, in
chronic myeloid leukemia (CML), quiescent therapy-resistant
stem cells were sensitized to tyrosine kinase inhibitors by
treatment with a pan-Bcl-2 inhibitor.14 In solid tumors, the role
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of Bcl-2 family members in regulating the stem cell compart-
ment is less clear. By analyzing the expression and relative
function of Bcl-2 and Bcl-XL in LCSC, we identified a prevalent
role of Bcl-XL in LCSC survival. Differently from chemother-
apy, ABT-737 showed a preferential cytotoxic activity towards
quiescent/slowly proliferating LCSC in vitro indicating a
potential use of this inhibitor to eradicate chemotherapy-
resistant LCSC. In vivo, ABT-737 blocked the progression of
LCSC-derived xenografts and reduced CSC content, sub-
stantiating its specific effect on the CSC compartment.
Altogether, these results indicate for the first time a key role
of Bcl-XL in LCSC, opening new perspectives for the
elimination of therapy-resistant cells.
Results
Phenotypic and functional characterization of LCSCs.
Four LCSC lines were isolated from NSCLC surgical speci-
mens (one large-cell neuroendocrine carcinoma, one adeno-
carcinoma and two squamous cell carcinomas; clinical and
mutational data are reported in Supplementary Figure 1)
and cultured in serum-free medium containing EGF and
basic-FGF as previously described.4 Such culture conditions
allow the growth of multicellular spheroids (MCSs) with
properties of CSC, as demonstrated by their ability to
generate tumors that phenocopy the original patient tumor
in immunocompromised mice (Figure 1a). LCSC can be
induced to differentiate by growth in adherent conditions
(described in Materials and Methods), where they acquire the
expression of cytokeratins and lose the expression of stem
cell markers such as Nanog (Figure 1b). LCSC MCS express
stem cell markers such as CD133, ALDH1 (detected as
ALDH activity) and c-kit (Figures 1c–e). Notably, none of the
three markers showed a high and consistent expression in all
the LCSC lines, indicating a phenotypic heterogeneity in
NSCLC stem cell marker expression as also reported by
recent studies.15 Drug resistance has been previously
demonstrated to be a feature of LCSC.4,6,16 As expected,
LCSCs used for this study were highly resistant to commonly
used antineoplastic agents (Figure 1f), whereas their
differentiated progeny and the commercial cell line H460
were overall more sensitive to drug-induced death. Alto-
gether, these observations substantiate the validity of LCSC
as cellular models in the search of new options for lung
cancer therapy.
Expression and RNA-mediated silencing of Bcl-2 family
members in LCSCs. Anti-apoptotic Bcl-2 family proteins
have a key role in cancer cell survival and have been recently
shown to contribute specifically to the maintenance of the
CSC population in hematological malignancies.13,14 In order
to evaluate the possible contribution of Bcl-2 family proteins
in LCSC, we assessed the expression of Bcl-2, Bcl-XL, Mcl-1,
Bim, Puma and Noxa in LCSC and in their differentiated
progeny by immunoblotting and flow cytometry analysis
(Figure 2a and Supplementary Figure 2a, respectively).
Bcl-XL and Mcl-1 were ubiquitously expressed in LCSC and
differentiated cells, whereas Bcl-2 was completely absent
from two of the four LCSC lines examined, as confirmed also
by analysis of LCSC RNA levels (Figure 2b). Pro-apoptotic
Bim, Puma and Noxa were variably expressed, with an
overall tendency to increase with differentiation (Figure 2a),
in line with the higher sensitivity of differentiated cells to
cytotoxic drugs. To address the relative importance of Bcl-2,
Bcl-XL and Mcl-1 in LCSC survival, we silenced the
expression of either factor with short duplexed RNA
oligonucleotides in LCSC line LC1 (which expresses both
Bcl-2 and Bcl-XL) and in LC4 (which does not express Bcl-2).
In addition, we double-silenced Bcl-2/Bcl-XL in LC1. Western
blot analysis of shRNA-treated LCSC showed that each
siRNA pool had a prevalent effect in silencing its specific
target (Figure 2c and Supplementary Figure 2c). Then, we
assessed the functional outcome of Bcl-2, Bcl-XL and Mcl-1
targeting in LCSC through analysis of cell viability, caspase
3/7 activation and clonogenicity. Bcl-2 silencing resulted in a
moderate (B25%) decrease in LCSC viability, no apparent
caspase 3/7 activation and modest inhibition of colony
number/size in semisolid culture (Figures 2d–g). Differently,
Bcl-XL silencing resulted in a marked (B75%) reduction in
cell viability and colony-forming capacity accompanied by
significant caspase 3/7 activation. Mcl-1 silencing also
resulted in strong (B75%) inhibition of LCSC viability and
colony formation (Figures 2d–g). Combined silencing of both
Bcl-2/Bcl-XL in LC1 resulted in slightly higher inhibition of cell
viability as compared with single Bcl-XL silencing (B80%)
and an increased effect on caspase activation and colony
formation, with the complete disappearance of large colonies
(Figures 2d–g). Single Bcl-XL silencing in LC4 resulted in
strong (B75%) inhibition of cell viability and colony formation
(Figures 2d–g). These results indicate a major role for Bcl-XL
and Mcl-1 in LCSC survival and a further increased
importance of Bcl-XL in LCSC devoid of Bcl-2.
The small-molecule BH3 mimetic ABT-737 inhibits
survival and self-renewal of LCSC in vitro. Given the
high in vitro efficacy of combined Bcl-2/Bcl-XL silencing, we
evaluated the effects of the Bcl-2/Bcl-XL inhibitor ABT-737 on
the survival of LCSC and of their differentiated counterparts.
ABT-737 induced a significant reduction of viability in all
LCSC lines starting from a 500-nM concentration (Figure 3a).
ABT-737 toxicity was generally lower in differentiated cells,
which in two out of four cases were sensitive only to the 1-mM
concentration (Figure 3a). In order to evaluate the relative
contribution of Bcl-2 and Bcl-XL inhibition in ABT-737-
mediated toxicity, we treated LCSC and differentiated cells
with the Bcl-2-selective inhibitor ABT-199. Such treatment
resulted only in a modest decrease in cell viability in one out
of four lines (Figure 3b). Likewise, ABT-737, but not ABT-
199, significantly reduced colony number and size in all the
LCSC lines (Figures 3c and d). These results indicate that
the effects of ABT-737 in LCSC are mainly mediated through
Bcl-XL inhibition, whereas single Bcl-2 inhibition had negli-
gible effects on cell survival. Propidium iodide staining and
flow cytometry analysis of cellular DNA in ABT-737-treated
LCSC showed that the decrease in cell number was actually
because of an accumulation of cells with fragmented DNA,
suggesting the occurrence of apoptosis.
ABT-737 preferentially eliminates quiescent/slow-
proliferating LCSC. Quiescent/slow-proliferating CSCs have
ABT-737 targets quiescent lung cancer stem cells
A Zeuner et al
1878
Cell Death and Differentiation
been identified in several tumors17–21 and in several cases
have been specifically shown to represent the chemotherapy-
resistant population (reviewed in Moore and Lyle22). In order
to determine whether LCSC populations separated according
to proliferation rates were differently affected by ABT-737
treatment, we stained LCSC with PKH26. This lipophilic dye is
segregated between daughter cells with each round of division
and therefore, after several days, is retained at high levels only
Figure 1 Phenotypic and functional characterization of LCSCs. (a) Hematoxylin–eosin-stained sections of patient tumors (upper panels) and of mouse xenografts (lower
panels) obtained with the indicated LCSC lines. Magnification  10, bar 50mm. LCNEC, large cell neuroendocrine carcinoma; SCC, squamous cell carcinoma; AC,
adenocarcinoma. (b) Immunofluorescence analysis of cytokeratins and Nanog expression in LCSC grown as tumor spheroids (Stem) or in adherent conditions (Differentiated).
DIC, differential interference contrast. Magnification  60,  2 zoom, bar 30mm. (c–e) Expression of CD133, ALDH-1 (measured indirectly as ALDEFLUOR positivity) and
c-kit (cKIT) detected by flow cytometry in the indicated LCSC lines. (f) Viability of LCSC lines (Stem) and of their differentiated counterparts (Diff) treated for 72 h with
gemcitabine 250 mM, paclitaxel 30 ng/ml, cisplatin 5 mg/ml or etoposide 10mg/ml. Bars represent mean±S.D.; *Pr0.05 and **Pr0.01 (n¼ 3). The NSCLC cell line H460
was used as a control
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Figure 2 Expression of Bcl-2 family members in stem/differentiated lung cancer cells and functional effects of RNA-mediated silencing. (a) Western blot analysis of Bcl-2,
Bcl-XL, Bim, Puma, Noxa and Mcl-1 expression in LCSC (Stem) and their differentiated progeny (Differentiated). (b) Real-time PCR analysis of Bcl-2, Bcl-XL and Mcl-1
transcripts in LCSC. (c) Western blot analysis of Bcl-2, Bcl-XL and Mcl-1 expression in LCSC LC1 (left and center) and LC4 (right) transfected with short-hairpin RNAs non-
targeting (Control) or directed against Bcl-2 (siBcl-2), Bcl-XL (siBcl-XL), combined (siBcl-2/XL) or Mcl-1 (siMcl-1). (d) Viability of LCSC LC1 and LC4 transfected as above. Bars
represent mean±S.D.; *Pr0.05 and ***Pr0.001 (n¼ 3). (e) Caspase 3/7 activation, expressed as an increase compared with controls, of LCSC LC1 and LC4 transfected
as above. Bars represent mean±S.D.; **Pr0.01 and ***Pr0.001 (n¼ 3). (f) Colony formation in soft-agar culture of LCSC LC1 and LC4 transfected as above (left). Bars
represent mean±S.D.; *Pr0.05, **Pr0.01 and ***Pr0.001 (n¼ 3). (g) Size of colonies formed in soft-agar by LCSC LC1 (left) and LC4 (right) transfected as above.
Asterisks refer to the statistical significance of the number of small (black bands), medium (grey bands) and large (white bands) colonies compared between each sample and
the control. Bars represent mean±S.D.; *Pr0.05, **Pr0.01 and ***Pr0.001 (n¼ 3)
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by slow-proliferating cells (Figure 4a). Ten days after PKH
staining, LCSCs were sorted into PKHlow and PKHhigh
populations according to dye retention (Figure 4b), treated
with ABT-737 or gemcitabine and cell viability was evaluated
after 72h as compared with mock-sorted cells. Quiescent/
slow-proliferating PKHhigh LCSCs were significantly more
sensitive to ABT-737 than rapidly proliferating PKHlow cells,
indicating that quiescent LCSCs have an increased depen-
dence on Bcl-2 family proteins for survival (Figure 4c).
By contrast, gemcitabine was more effective on rapidly
proliferating PKHlow cells, in line with the inability of
chemotherapy to eradicate a fraction of therapy-resistant
LCSC. Then, we analyzed the levels of pro- and anti-apoptotic
Bcl-2 family members in PKHlow and PKHhigh cells using flow
cytometry in two LCSC lines (Figure 4d and Supplementary
Figure 3) and we found that Bcl-XL was consistently
expressed at higher levels in PKHhigh cells, according to their
increased sensitivity to ABT-737. Bcl-2 was also expressed at
higher levels in PKHhigh LC1. In addition, we found that Noxa
was significantly more expressed by quiescent PKHhigh cells
Figure 3 Effect of ABT-737 on LCSC in vitro. (a) Viability of LCSC (Stem) and their differentiated counterparts (Diff) treated with increasing doses of ABT-737
(100 nM–1mM) for 72 h. Bars represent mean±S.D.; *Pr0.05, **Pr0.01 and ***Pr0.001 (n¼ 5). (b) Viability of LCSC treated with increasing doses of ABT-199 (100 nM–1mM)
for 72 h. Bars represent mean±S.D.; *Pr0.05 (n¼ 3). (c) Colony formation in soft-agar culture of LCSC plated in the presence of 500 nM ABT-737 (ABT-737) or 500 nM
ABT-199 (ABT-199). Bars represent mean±S.D.; *Pr0.05 and **Pr0.01 (n¼ 3). (d) Size of colonies formed in soft-agar assay by LCSC LC1 treated as in c.
Bars represent mean±S.D.; **Pr0.01 and ***Pr0.001 (n¼ 3). Asterisks refer to the statistical significance of the number of small (black bands), medium (grey bands) and
large (white bands) colonies compared between each sample and the control. (e) Propidium iodide staining and flow cytometry analysis of LCSC untreated (upper panels) or
treated for 72 h with 500 nM ABT-737 (lower panels). Numbers refer to the percentage of events included in the P6 (hypodiploid) area of the plot
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as compared with PKHlow cells in the two LCSC lines
examined, although the significance of this finding is unclear.
The other Bcl-2 family members Mcl-1, Bim and Puma
showed a trend towards a higher expression in PKHhigh cells
but the overall difference between PKHlow and PKHhigh cells
was not significant. Altogether, these results substantiate a
role of Bcl-XL in the survival of quiescent LCSC and support
further investigations on targeted therapeutic strategies.
Functional characterization of ABT-737-induced death in
LCSC. To gain insights into the mechanisms of ABT-737-
induced death in LCSC, we first examined the involvement of
mitochondria, which represent the preferential cellular loca-
tion of Bcl-2 and Bcl-XL and the hub of apoptosis-related
events.23 First, we evaluated mitochondrial membrane
potential through JC-1 staining of live LCSC MCS. Whereas
untreated MCS showed red JC-1 aggregates typical of
healthy mitochondria, a significant proportion of ABT-737-
treated MCS displayed only green JC-1 monomers,
indicating the occurrence of mitochondrial depolarization
(Figure 5a). Immunofluorescence staining of dissociated LCSC
showed redistribution of cytochrome c and apoptosis-inducing
factor (AIF) from mitochondria to the nucleus and cytoplasm
of ABT-737-treated cells (Figures 5b and c). Mitochondrial
depolarization, together with cytochrome c and AIF release,
indicate that ABT-737-induced death has some features of
apoptosis. Modest (three- to sixfold increase) caspase 3/7
activation was detectable in 2/4 LCSC lines treated with ABT-
737, reaching maximal levels after 16 h of stimulation
(Figures 5d and e). As overproduction of reactive oxygen
Figure 4 ABT-737 preferentially eliminates quiescent/slow cycling LCSC. (a) Representative confocal image of a LCSC spheroid (line LC4) 10 days after PKH26 staining.
Red: PKH26, blue: Dapi. Magnification  60, bar 10mm. (b) Representative FACS profile of LCSC cell populations (line LC4) selected for sorting 10 days after PKH24
staining (PKH26 day 10) as compared with the unstained control (Untreated). (c) LCSC lines LC1 and LC4 mock-sorted (Untreated) or sorted into PKH26 high and PKH26 low
populations were incubated for 72 h with 500 nM ABT-737 or 250mM gemcitabine and cell viability was assessed as described in Materials and Methods. Bars represent
mean±S.D.; *Pr0.05, **Pr0.01 and ***Pr0.001 (n¼ 3). (d) Levels of Bcl-2 family members in PKH26 high (PKH high) and PKH26 low (PKH low) LCSC populations
(lines LC1 and LC4) measured by flow cytometry and expressed as normalized mean fluorescence intensity. Bars represent the mean±S.D.; *Pr0.05, **Pr0.01 and
***Pr0.001 (n¼ 4). Raw data of one representative experiment are shown in Supplementary Figure 3
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species (ROS) and reactive nitrogen species (RNS) has
been implicated in cell death induction, we determined
whether oxidative/nitrosative stress was implicated in ABT-
737-induced death in LCSC. To do this, we treated cells with
ABT-737 in the presence of radical scavengers such as
superoxide dismutase, catalase (ROS scavengers), carboxy-
PTIO and uric acid (blockers of nitrogen radicals). Surpris-
ingly, neither of these compounds was able to significantly
reduce ABT-737-induced death (Figure 5f), suggesting that
ROS/RNS are dispensable for ABT-737-induced LCSC
death. Finally, we determined whether ABT-737-induced
death could be affected by caspase inhibition or RIP-1
inhibition, thus indicating prevalent features of caspase-
mediated apoptosis or necroptosis, respectively. LCSCs
were treated for 48 h with ABT-737 in the presence of the
pan-caspase inhibitor zVAD, of the RIP-1 inhibitor necrosta-
tin or with a combination of the two (Figure 5g). To assess
the possible baseline toxicity of the inhibitors, LCSCs were
also treated with the single drugs or with their combination in
the absence of ABT-737. Controls of inhibitor efficacy were
represented by Jurkat leukemia cells treated with TRAIL and
by L929 mouse fibrosarcoma cells treated with TNF
(Supplementary Figure 4). zVAD and necrostatin as single
agents were unable to inhibit ABT-737-induced LCSC death,
which was even slightly enhanced in the presence of the
inhibitors. The simultaneous presence of the two inhibitors
was similarly unable to block ABT-737-induced death,
indicating that it occurs through mechanisms alternative to
caspase-dependent apoptosis or necroptosis.
ABT-737 blocks the growth of CSC-derived tumor
xenografts and reduces stem cell content in vivo. To
determine the in vivo antitumor efficacy of ABT-737, we
generated subcutaneous tumor xenografts by injecting LCSC
into immunocompromised (NOD/SCID gamma-chain-defi-
cient) mice. When tumors reached the approximate volume
of 200–250mm3, mice were treated for 3 weeks with either
vehicle alone, gemcitabine or ABT-737. Experiments were
performed both with LC1 (Figure 6a) and LC4 (Figure 6b)
LCSC lines, as representatives of cells expressing both Bcl-
2/Bcl-XL or only Bcl-XL, respectively. In both cases, ABT-737
treatment abrogated tumor growth, whereas gemcitabine
treatment had only a moderate inhibitory effect (Figures 6a
and b). Hematoxylin–eosin evaluation of tissue structure
showed the presence of necrotic areas and decreased
cellularity in ABT-737-treated samples as compared with
control or gemcitabine-treated samples (Figure 6c). To gain
more insights into the ability of ABT-737 to target LCSC
in vivo, we performed double stainings for CD133 and either
terminal deoxynucleotidyl transferase-mediated dUTP nick
end labeling (TUNEL; to detect the occurrence of DNA
fragmentation), poly-ADP-ribose-polymerase (PARP) clea-
vage or caspase-3 activation in tumor xenografts of the
LCSC line LC1 treated with ABT-737. Positivity for CD133
was often associated with TUNEL staining, cleaved PARP
and active caspase-3 in ABT-737-treated samples but not in
chemotherapy-treated samples, indicating that ABT-737
treatment induces LCSC death in vivo (Supplementary
Figure 5). This hypothesis was substantiated by the
evaluation of residual LCSC numbers at the end of treatment,
which was measured with FACS analysis of ALDH activity
(ALDEFLUOR) in dissociated xenograft cells. We found a
significantly reduced content of ALDEFLUOR-positive cells
in ABT-737-treated xenografts as compared with control
xenografts derived from LC1 and LC4 (Figures 6d and e). By
contrast, gemcitabine treatment resulted in a significant
increase in ALDEFLUOR-positive cells in LC1 and in LC4,
suggesting that gemcitabine antineoplastic activity is due
mainly to an effect on non-stem tumor cells.
Discussion
The advent of molecularly targeted therapies has increased
survival in a subset of lung cancer patients but did not radically
change disease outcome because of the invariable occur-
rence of therapy resistance and tumor relapse. CSCs have
been indicated as the population responsible for therapy
resistance, because of their increased availability of drug-
protectivemechanisms.24 Quiescence is a common feature of
drug-resistant cells and has been associated with stem cell
traits in several tumors.22 In glioblastoma, quiescent CSCs
have been demonstrated to selectively resist temozolomide
treatment and to regenerate the tumor after chemotherapy.25
Interestingly, quiescent CSC populations in leukemias have
been recently shown to express high levels of Bcl-2 and to rely
on this factor for oxidative phosporylation, which represents
their main energy-generating pathway. In AML and CML, Bcl-
2 inhibition by ABT-737 selectively targets quiescent CSC,
representing a proof-of-principle for investigating a similar
approach in solid tumors.13,14 NSCLC commercial cell lines
have been reported to be moderately sensitive to ABT-737 as
a single agent.26,27 However, lung tumor cells that survive
treatment with EGFR kinase inhibitors show decreased
proliferation and increased sensitivity to ABT-737,28 suggest-
ing the existence of a link between quiescence, Bcl-2 family
members and drug resistance in lung cancer cells.
In patient-derived LCSC spheroids we found a constant
expression of Bcl-XL, but not Bcl-2, confirming the observa-
tions reported by Fan et al.28 in lung cancer cell lines.
Importantly, Bcl-XL inhibition was more effective than Bcl-2
inhibition in decreasing LCSC viability and clonogenic
capacity in LCSC lines expressing both factors. This
observation is consistent with the fact that Bcl-XL binds a
larger number of pro-apoptotic partners than Bcl-2 and seems
to have amajor role in the control of drug-induced apoptosis,29
thus emerging as a promising therapeutic target. However,
future targeted therapies specifically directed against Bcl-XL
would have to face the problem of therapy-induced thrombo-
cytopenia, as Bcl-XL has been shown to be essential for
platelet survival.30 One way to overcome this obstacle may be
the design of novel Bcl-XL inhibitors with selective toxicity
against tumor cells but not against platelets, based on the
difference between the survival complexes active in the two
cellular systems (Bcl-XL/Bim in tumor cells and Bcl-XL/Bak in
platelets).29
ABT-737 induced in LCSC a form of cell death that was
insensitive to inhibition of caspases, of ROS/RNS and of
necroptosis. The occurrence of mitochondrial depolarization
and cytochrome c release suggests that ABT-737 may induce
in LCSC a non-canonical form of apoptotic cell death that can
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include caspase activation as a non-essential pathway.
Notably, ABT-737-induced death has been shown to be
ROS-dependent in other cellular systems.31,32 This difference
may be ascribed to the peculiar oxidative state of CSCs, which
have been reported to have low levels of ROS and increased
expression of free radical-scavenging systems.9,33
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The ability of ABT-737 to target LCSC was confirmed
in vivo, where ABT-737 treatment arrested the growth of
LCSC-derived tumors and significantly reduced the amount
of stem cells present in the xenograft. This finding has
important implications for the therapy of NSCLC, suggesting
that treatmentwithABT-737 could effectively complement a first
line of therapywith chemotherapy or tyrosine kinase inhibitors in
order to target residual quiescent LCSC. Owing to its ability to
preferentially kill quiescent LCSC, ABT-737 treatment may not
result in a fast macroscopic reduction of tumor size but may
have long-term beneficial effects on the rates of tumor growth
and relapse. Clinical trials designed to specifically evaluate
this endpoint will help to clarify the usefulness of Bcl-XL
inhibition in the treatment of NSCLC patients.
Materials and Methods
Antibodies and reagents. ABT-737 was provided by AbbVie (Abbott Park,
IL, USA). ABT-199 was purchased from Selleckchem (Munich, Germany). CD133/
1-PE (used for flow cytometry) and CD133/2 (used for immunofluorescence) were
from Miltenyi Biotec (Bergisch Gladbach, Germany). ALDEFLUOR assay was from
Aldagene (Durham, NC, USA). Nanog and AIF antibodies were from Cell
Signaling Technology Inc. (Danvers, MA, USA). Pan-cytokeratin antibody was
from Dako (Glostrup, Denmark). Cytochrome c antibody was from BD Biosciences
(San Jose´, CA, USA). Cleaved caspase 3 antibody was from Upstate
Biotechnology (Lake Placid, NY, USA). Alexa Fluor-conjugated secondary
antibodies were from Invitrogen-Molecular Probes (Eugene, OR, USA). TUNEL
was from Roche Molecular Biochemicals (Indianapolis, IN, USA). Bcl-XL (clone
H5), Bcl-2 (clone DC-21), Mcl-1 (clone C-2), Bim (clone H-5), Puma (clone H-136),
Noxa (clone FL-54) and necrostatin were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Monoclonal antibodies anti-actin, tubulin and cleaved PARP were
from Sigma Aldrich (St Louis, MO, USA). Secondary anti-mouse and anti-rabbit
antibodies coupled to horseradish peroxidase were from GE Healthcare (Uppsala,
Sweden).
CSC isolation and culture. LCSCs were isolated as previously described
from surgically resected tumor samples through selective culture in serum-free
mediun containing EGF 20 ng/ml and basic FGF 10 ng/ml (PeproTech, London,
UK).4 Nontreated polystyrene flasks (Thermo Fischer Scientific, Waltham, MA,
USA) were used to reduce cell adherence and support growth of LCSC as
multicellular spheres. Regular thawing of early-passage cells was carried out to
avoid the accumulation of culture-related changes. LCSC differentiation was
obtained by culture for 24 h in DMEM 10% plus fetal bovine serum (Gibco-
Invitrogen, Carlsbad, CA, USA) and for 5 additional days in Bronchial Epithelial
Cell Growth Medium (Cambrex, East Rutherford, NJ, USA).
Viability assay. LCSC viability upon treatment with chemotherapeutic drugs,
ABT-737 and other inhibitors was determined with the CellTiter-Glo assay
(Promega, Madison, WI, USA) according to the manufacturer’s instructions.
Briefly, 1.5 103 dissociated LCSC, H460, Jurkat or TF-1 cells were plated in
96-well flat bottom plates. Chemotherapeutic agents were added at the following
final concentrations: gemcitabine 250mM, paclitaxel 30 ng/ml, cisplatin 5 mg/ml
and etoposide 10mg/ml. Pan-caspase inhibitor z-Val-Ala-Asp-fluoromethylketone
(40mM; Bachem, Bubendorf, Switzerland) or 25 mM necrostatin (Santa Cruz
Biotechnology) were added 1 h before ABT-737 and cells were processed after 3
additional days. TNF-a was kindly provided by Dr. TL Haas (see Acknowl-
edgements and studies by Haas et al.,34 Enyedy et al. 35 and Ewald et al.36). Free
radical scavengers used to inhibit ROS (superoxide dismutase and catalase
1 mg/ml each), nitric oxide (carboxy-PTIO 0.1mM) and peroxynitrite (uric acid
1 mM) were added 24 h before ABT-737 and cell viability was determined after 3
additional days of incubation.
RNA interference. In all, 1.25 105 LCSCs were plated on six-well plates in
antibiotic-free culture medium and incubated for 4 h at 37 1C in the presence of
320 nM ON-TARGETplus SMARTpool siRNA (D-001810-01-055 Non-targeting
siRNA, L-003307-00-0005 Human Bcl-2 and L-003458-00-0005 Human Bcl-XL,
M-004501-08-0005 Human Mcl-1 Dharmacon/Thermo Scientific, Lafayette, CO,
USA) and 5 ml Lipofectamine 2000 (Invitrogen). After 4 h the transfection mixture
was substituted with LCSC culture medium and cells were analyzed for protein
expression, viability and caspase activation at the indicated times.
PKH26 staining. LCSC spheroids were dissociated with TrypLE Express
(Invitrogen) and stained for 1 h at 37 1C with 1 : 500 PKH26 (Sigma-Aldrich), then
washed extensively with PBS and cultured for 10 additional days. Cells were then
separated with a FACS Aria (BD Biosciences) into PKHlow and PKHhigh fractions.
Control cells did not undergo PKH26 staining but were mock-sorted to induce
similar stress conditions as in the other sorted samples.
Western blotting. LCSC spheroids were lysed in 1% NP40 lysis buffer
(20 mM Tris HCl pH 7.2, 200 mM NaCl, 1% NP40) supplemented with protease
inhibitor cocktail and phosphatase inhibitor cocktails I and II (all from Sigma-
Aldrich). Lysate concentrations were determined by the Bradford assay (Bio-Rad
Laboratories, Hercules, CA, USA). Proteins were loaded on a 4–12% precast gel
(Invitrogen) and transferred to nitrocellulose membranes. Blots were blocked with
TBST 5% nonfat dry milk and incubated overnight at 4 1C with primary antibodies,
and then incubated for 45 min with secondary HRP-conjugated antibodies
dissolved in TBST 1% BSA. Chemiluminescence was detected with Super
SignalWest Pico (Thermo Fisher Scientific/Pierce, Waltham, MA, USA).
Clonogenicity assay. The clonogenic capacity of LCSC was assessed by
plating 500 cells per well in triplicate in 24-well plates containing a soft agar bilayer
(0.3% top and 0.4% bottom layer, SeaPlaque Agarose, Cambrex) with or without
ABT-737 or ABT-199. Cultures were incubated at 37 1C for 21 days. Colonies were
stained with crystal violet (0.01% in 10% methanol) and counted under a light
microscope. Data shown represent the percentage of colonies normalized to the
number of plated cells.
Cell cycle, apoptosis, necroptosis and caspase activation
assays. Cell cycle analysis was performed by staining dissociated LCSC
spheroids with 50mg/ml propidium iodide dissolved in buffer 0.1% trisodium
citrate, 9.65 mM NaCl, 0.1% NP40, 200 mg/ml RNAse for 1 h at room temperature.
Samples were analyzed with a FACS Canto flow cytometer (BD Biosciences).
Evaluation of caspase activity was determined with the Apo-ONE Homogeneous
Caspase-3/7 Assay kit (Promega) at indicated times. Luminescent or fluorimetric
assay signals were read using a DTX880 multimode microplate reader (Beckman
Coulter, Brea, CA, USA). The occurrence of necroptosis was evaluated by treating
Figure 5 Characterization of ABT-737-induced death in LCSC. (a) Left: immunofluorescence staining of live intact spheroids, untreated or treated with 500 nM ABT-737
for 48 h with the mitochondrial membrane sensor JC-1, indicating the presence of depolarized mitochondria as loss of red JC-1 aggregates. Magnification  60,  3.5 zoom,
bar 20mm. Right: quantification of JC1 monomers and aggregates in untreated and ABT-737-treated cells on confocal samples; **Pr0.01 (n¼ 3). (b) Left: cytochrome
c localization in LCSC pre-stained with Mitotracker Red and untreated or treated with 500 nM ABT-737 for 48 h. Magnification  60,  3 zoom, bar 20mm. Right: quantification of
Mitotracker/cytochrome c colocalization in confocal samples; **Pr0.01 (n¼ 3). (c) Left: localization of apoptosis inducing factor (AIF) in LCSC pre-stained with Mitotracker Red
and untreated or treated with 500 nM ABT-737 for 48 h. Magnification  60, zoom  3, bar 20mm. Right: quantification of Mitotracker/AIF colocalization in confocal samples;
*Pr0.05 (n¼ 3). The LCSC line LC1 was used to produce images shown in a–c. (d) Caspase 3/7 activation, expressed as fold increase as compared with untreated samples, in
LCSC lines treated for 72 h with 500 nM ABT-737. The hematopoietic cell line TF-1 treated with 0.5mM doxorubicine was used as positive control. Bars represent mean±S.D.;
**Pr0.01 (n¼ 3). (e) Time-course evaluation of caspase 3/7 activation in LC1 during the first 48 h of treatment with 500 nM ABT-737. (f) Viability of LCSC treated for 72 h with
500 nM ABT-737, alone (ABT-737) or in the presence or in the absence of free radical scavengers: SOD, superoxide dismutase; CAT, catalase; CPTIO, 2-(4-Carboxyphenyl)-
4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide. Bars represent mean±S.D.; **Pr0.01 (n¼ 4). (g) Viability of LCSC lines LC1-4 treated for 48 h with either 500 nM ABT-737,
40mM zVAD, 25mM necrostatin or the indicated combinations; *Pr0.05, **Pr0.01 (n¼ 3)
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Figure 6 ABT-737 blocks the growth of LCSC-derived xenografts and reduces LCSC content in vivo. (a) Growth of tumor xenografts derived from the LCSC line LC1 in
mice treated with vehicle (Control), gemcitabine or ABT-737 as described in Materials and Methods (left), tumor weight at the end of the experiment and representative picture
of the tumors (right). Bars represent mean±S.D.; *Pr0.05 and ***Pr0.001 (n¼ 3). (b) Growth of tumor xenografts derived from the LCSC line LC4 and treated as above
(left), tumor weight at the end of the experiment and representative picture of the tumors (right). Bars represent mean±S.D.; ***Pr0.001 (n¼ 3). (c) Hematoxylin–eosin-
stained sections of xenografts derived from the LCSC lines LC1 and LC4 after 3 weeks of treatment with vehicle (Control), gemcitabine or ABT-737 as described above;  10
magnification, bar 50mm. (d) Fold variation of ALDEFLUOR-positive cells in gemcitabine- and ABT-737-treated tumor xenografts obtained with the LC1 LCSC line as
compared with vehicle-treated controls. Bars represent mean±S.D.; **Pr0.01 and ***Pr0.001 (n¼ 3). (e) Fold variation of ALDEFLUOR-positive cells in gemcitabine and
ABT-737-treated tumor xenografts obtained with the LC4 LCSC line as compared with vehicle-treated controls. Bars represent mean±S.D.; *Pr0.05
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LCSC with 500 ng/ml ABT-737 plus 25 mM necrostatin for 48 h or L929 mouse
fibrosarcoma cells with 100 ng/ml TNF plus zVAD 40 mM plus 25mM necrostatin
for 24 h.
Quantitative real-time PCR. Total RNA was extracted with TRIzol
(Invitrogen). RNA (1 mg) was reverse-transcribed with M-MLV reverse transcrip-
tase (Gibco-Invitrogen) and cDNA was used as template in the subsequent PCR
reactions. SYBR Green specific primers (Life Technologies, Carlsbad, CA, USA)
were used for Bcl-2 (forward primer: 50-CGGAGGCTGGGATGCCTTTG-30;
reverse primer: 50-GATGCAAGCTCCCACCAGGG-30), Bcl-XL (forward primer:
50-GCCTAAGGCGGATTTGAATCTCT-30; reverse primer: 50-GCTCCCGGTTGC
TCTGAGAC-30) and Mcl-1 (forward primer: 50-AGGCTGGGATGGGTTTGTGG-30;
reverse primer: 50-TGGCTAGGTTGCTAGGGTGC-30) quantitative PCR. Normal-
ization was performed using GAPDH as reference (forward primer: 50-GAGTCA
ACGGATTTGGTCGT-30; reverse primer: 50-TGGAAGATGGTGATGGGATT-30).
Values are expressed in terms of 2DDCt where DDCt¼DCtsample DCtcalibrator.;
DCt is the difference in threshold cycles between the specific RNA and GAPDH
amplicons, and Ct is a parameter given by the StepOne Plus Real-Time PCR
software (Life Technologies) by negative correlation with an internal reference
dye (ROX).
Flow cytometry. For flow cytometry assays, MCS or xenograft-derived cells
were dissociated as single cells, washed with PBS and incubated with the
appropriate dilutions of control or specific antibodies for 45 min at room
temperature. Fluorescence intensity of labeled cells was evaluated with a FACS
Canto (BD Biosciences). 7-Aminoactinomycin D (10 mg/ml; 7-AAD; Sigma-Aldrich)
was added for dead cell exclusion. For the detection of intracellular antigens, cells
were fixed in 2% paraformaldehyde and permeabilized in 0.1% Triton X-100
(Bio-Rad Laboratories) and then incubated 45 min at room temperature with
primary antibodies dissolved in PBS 1% BSA. After being washed in PBS, cells
were incubated with AlexaFluor-647 secondary antibodies for 30 min at room
temperature in the dark.
Immunofluorescence analysis of cultured cells and xenograft
sections. LCSC spheroids or dissociated cells were cytospun on polylysine-
coated glass slides, whereas differentiated cells were grown on matrigel-coated
coverslips. Cells were fixed in 2% paraformaldehyde and permeabilized in 0.1%
Triton X-100 and then incubated overnight at 4 1C with primary antibodies
dissolved in PBS 3% BSA. After being washed in PBS, cells were incubated with
Alexa Fluor-conjugated secondary antibodies for 45 min at room temperature in
the dark, stained for 15 min with Dapi (Invitrogen) diluted in PBS 3% BSA and
mounted with Prolong-Gold antifade (Invitrogen). Negative controls were prepared
by omitting staining with the primary antibody. To determine mitochondrial
membrane potential in live cells, LCSC spheroids were incubated for 1 h at 37 1C
with 10mM JC-1 (Invitrogen). Cytochrome c and AIF release from mitochondria
were determined by staining live cells for 30 min at 37 1C with 100 nM Mitotracker
CMXRos (Invitrogen). Cells were then fixed, permeabilized and incubated with the
respective monoclonal antibodies as described above. Tumor xenografts
previously embedded in optimal cutting temperature compound (OCT) and frozen
at  80 1C were cut into 5-mm-thick tumor sections with a cryomicrotome (Kriostat
1720 MGW Leitz, Melville, NY, USA). Sections were fixed in 4% paraformaldehyde
and permeabilized in 0.1% Triton X-100, then stained overnight at 4 1C with
primary antibodies, incubated with fluorochrome-conjugated secondary antibodies
and counterstained with Dapi. For in situ apoptosis detection in tumor xenograft
sections, TUNELreaction was performed using the In situ Cell Death Detection kit
(Roche Molecular Biochemicals) according to the manufacturer’s instructions.
Slides were analyzed using an Olympus FV-1000 confocal microscope equipped
with Ultraplan Apochromatic  60 N.A.1.35 and  40 N.A. objectives and the
Olympus Fluoview software (Olympus, Tokyo, Japan).
Mice treatment. All animal procedures were performed according to the
national Animal Experimentation guidelines (D.L.116/92) upon approval of the
experimental protocol by the Institutional Animal Experimentation Committee.
Female 6–8 weeks old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (The
Jackson Laboratory, Bar Harbor, ME, USA) were subcutaneously injected with
5 105 cells resuspended in 100ml Matrigel/LCSC medium (1 : 1). Mice were kept
under pathogen-free conditions with food and water ad libitum. Tumor diameter was
measured by using an external digital caliper and calculated as the mean value
between the shortest and the longest diameters. When tumor diameters reached an
approximate volume of 200–250 mm3, the treatment was started. The control group
(n¼ 6) was treated daily by injecting intraperitoneally (i.p.) a vehicle solution
composed of 100ml of 30% PEG, 5% Tween 80 and 65% D5W (5% dextrose in
water) at pH 4–4.5. The ABT-737 group (n¼ 6) was treated by injecting i.p. the
compound daily (100 mg/kg) dissolved in vehicle solution. The chemotherapy group
(n¼ 6) was treated by injecting i.p. gemcitabine (60 mg/kg) resuspended in PBS
twice a week. Three weeks after the beginning of treatment, the mice were killed by
cervical dislocation and tumors were removed, weighted and processed for flow
cytometry analysis. For analysis of DNA fragmentation (TUNEL), PARP or caspase-
3 cleavage, a short-term treatment with ABT-737 was performed by injecting i.p. the
vehicle solution, ABT-737 150 mg/kg or gemcitabine 100 mg/kg. Forty-eight hours
after treatment mice were killed and tumors were removed, embedded in OCT and
frozen at  80 1C for subsequent immunofluorescence analysis.
Statistical analysis. The statistical significance of the results was evaluated
by ANOVA and Bonferroni post tests. All statistical tests were performed using
GraphPad Prism v.4.0 for Windows (GraphPad Software, San Diego, CA, USA,
www.graphpad.com) and the threshold for statistical significance was set at 0.05.
P-values are displayed on the graphs using a single asterisk for significances
ranging from 0.05 to 0.01, two asterisks for values between 0.001 and 0.01 and
three asterisks for values below 0.001.
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